Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Annals of Oncology

• Publication date

  2009-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/annonc/mdn679PMID 19088172
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phenotype of bone metastases of nonsmall cell lung cancer: Epidermal growth factor receptor expression and KRAS mutational status

  2008cited by this paper
• Detection of mutations in EGFR in circulating lung-cancer cells.

  2008cited by this paper
• Heterogeneity of epidermal growth factor receptor mutations within a mixed adenocarcinoma lung nodule.

  2008cited by this paper
• A Blood-Based Test for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2006cited by this paper
• High sensitivity detection of epidermal growth factor receptor mutations in the pleural effusion of non‐small cell lung cancer patients

  2006cited by this paper
• Epidermal growth factor receptor mutations in needle biopsy/aspiration samples predict response to gefitinib therapy and survival of patients with advanced nonsmall cell lung cancer

  2006influential reference
• EGFR and KRAS mutations as criteria for treatment with tyrosine kinase inhibitors: retro- and prospective observations in non-small-cell lung cancer.

  2006cited by this paper
• Ethnic differences in response to epidermal growth factor receptor tyrosine kinase inhibitors.

  2006cited by this paper
• EGFR mutations in patients with brain metastases from lung cancer: association with the efficacy of gefitinib.

  2006cited by this paper
• Comparison of the epidermal growth factor receptor gene and protein in primary non-small-cell-lung cancer and metastatic sites: implications for treatment with EGFR-inhibitors.

  2006cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Epidermal growth factor receptor activating mutations in Spanish gefitinib-treated non-small-cell lung cancer patients.

  2005cited by this paper
• The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• The Biology of Epidermal Growth Factor Receptor in Lung Cancer

  2004cited by this paper
• Gene Expression Signatures, Cancer Cell Evolution and Metastatic Progression

  2004cited by this paper
• Heterogeneity within and between primary colorectal carcinomas and matched metastases as revealed by analysis of Ki-ras and p53 mutations.

  2004cited by this paper
• Pathology and genetics of tumours of the lung , pleura, thymus and heart

  2004cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy.

  2002cited by this paper
• Comparison of accumulated allele loss between primary tumor and lymph node metastasis in stage II non-small cell lung carcinoma: implications for the timing of lymph node metastasis and prognostic value.

  2002cited by this paper
• Chromosomal imbalances of primary and metastatic lung adenocarcinomas

  2002cited by this paper
• Discordance between K-ras mutations in bone marrow micrometastases and the primary tumor in colorectal cancer.

  2001cited by this paper
• TNM Classification of Malignant Tumors

  1998cited by this paper
• Mode of spread in the early phase of lymphatic metastasis in non-small-cell lung cancer: significance of nodal micrometastasis.

  1996cited by this paper
• Frequent allelic losses on chromosomes 2q, 18q, and 22q in advanced non-small cell lung carcinoma.

  1994cited by this paper
• Genetic analysis of epidermal growth factor action: assignment of human epidermal growth factor receptor gene to chromosome 7.

  1980cited by this paper

• Molecular testing and targeting for solid tumors with CNS metastases

  2025cites this paper
• Genetic composition and evolutionary trajectories of brain metastasis in non-small-cell lung cancer.

  2025cites this paper
• The interplay between autophagy and apoptosis: its implication in lung cancer and therapeutics.

  2024cites this paper
• Bone metastasis in non-small-cell lung cancer: genomic characterization and exploration of potential targets

  2024cites this paper
• Molecular evolution of central nervous system metastasis and therapeutic implications.

  2024cites this paper
• Predicting the T790M mutation in non-small cell lung cancer (NSCLC) using brain metastasis MR radiomics: a study with an imbalanced dataset

  2024cites this paper
• Methodological and TNM Focus-Based Comparison of EGFR Mutation Status in Non-Small-Cell Lung Carcinomas

  2024cites this paper
• Therapeutic Opportunities for Biomarkers in Metastatic Spine Tumors

  2024cites this paper
• Outcomes in non‐small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first‐line epidermal growth factor receptor tyrosine kinase inhibitors: A large real‐world cohort study

  2024cites this paper
• Adopted neoplastic cells and the consequences of their existence

  2023cites this paper
• BRAIN METASTASES AND NEXT-GENERATION ANTICANCER THERAPIES: A SURVIVAL GUIDE FOR CLINICIANS.

  2023cites this paper
• Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor

  2023cites this paper
• Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports

  2023cites this paper
• Genomic landscape and actionable mutations of brain metastases derived from non–small cell lung cancer: A systematic review

  2023cites this paper
• Emerging Systemic Treatment Perspectives on Brain Metastases: Moving Toward a Better Outlook for Patients.

  2022cites this paper
• Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies

  2022cites this paper
• Role of p53 in Human Cancers

  2022cites this paper
• Correlation of EGFR mutation subtypes and survival in surgically treated non-small cell lung cancer brain metastasis.

  2022cites this paper
• Radiomic Signatures for Predicting EGFR Mutation Status in Lung Cancer Brain Metastases

  2022cites this paper
• Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer

  2022influential citation
• Heterogeneity and Clinical Effect of Epidermal Growth Factor Receptor in Primary Lung and Brain Metastases of Nonsmall Cell Lung Cancer.

  2022cites this paper
• Concordance of Cytological Specimens with Histological Tissue for Detection of Epidermal Growth Factor Receptor Mutation in Non-Small Cell Lung Cancer: A Systematic Review

  2021cites this paper
• Precision medicine biomarkers in brain metastases: applications, discordances, and obstacles

  2021cites this paper
• Ovarian Cancer: Towards Personalizing Ovarian Cancer Treatments Using Patient-Derived Organoids

  2021cites this paper
• The Role of Whole Exome Sequencing in Distinguishing Primary and Secondary Lung Cancers

  2021cites this paper
• Molecular Profiles of Brain Metastases: A Focus on Heterogeneity

  2021cites this paper
• Expression of pannexin1 in brain metastases derived from lung cancer

  2021cites this paper
• Experimental Study of Almonertinib Crossing the Blood-Brain Barrier in EGFR-Mutant NSCLC Brain Metastasis and Spinal Cord Metastasis Models

  2021cites this paper
• Genomic landscape of metastatic lung adenocarcinomas from large-scale clinical sequencing

  2021cites this paper
• Rapid Tissue Donation (RTD) for Oncology Research

  2021cites this paper
• Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance

  2021cites this paper
• Tyrosine Kinase Inhibitors Could Be Effective Against Non-small Cell Lung Cancer Brain Metastases Harboring Uncommon EGFR Mutations

  2020cites this paper
• Diffusion tensor and postcontrast T1-weighted imaging radiomics to differentiate the epidermal growth factor receptor mutation status of brain metastases from non-small cell lung cancer

  2020cites this paper
• Minimal residual disease in advanced or metastatic solid cancers: the G0-G1 state and immunotherapy are key to unwinding cancer complexity.

  2020cites this paper
• 非小细胞肺癌原发灶与转移部位驱动基因状态一致性的研究进展

  2020cites this paper
• A study on different therapies and prognosis-related factors for brain metastases in lung adenocarcinoma patients with driver mutation

  2020cites this paper
• The role of percutaneous CT-guided biopsy of an adrenal lesion in patients with known or suspected lung cancer

  2020cites this paper
• Contrast-enhanced T1-weighted image radiomics of brain metastases may predict EGFR mutation status in primary lung cancer

  2020cites this paper
• Lung Adenocarcinoma with Metachronous Ovarian Metastasis: a long survival case report

  2020cites this paper
• Using genomics to differentiate multiple primaries from metastatic lung cancer.

  2019cites this paper
• Chemical pleurodesis – a review of mechanisms involved in pleural space obliteration

  2019cites this paper
• Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications

  2019cites this paper
• ALK rearrangement: a high-frequency alteration in ovarian metastasis from lung adenocarcinoma

  2019cites this paper
• Discordance of Epidermal Growth Factor Receptor Mutation between Brain Metastasis and Primary Non-Small Cell Lung Cancer

  2019influential citation
• Clinical Validation of Discordant Trunk Driver Mutations in Paired Primary and Metastatic Lung Cancer Specimens.

  2019influential citation
• Upfront Cranial Radiotherapy Followed by Erlotinib Positively Affects Clinical Outcomes of Epidermal Growth Factor Receptor-mutant Non-small Cell Lung Cancer With Brain Metastases

  2019cites this paper
• Comparative study of EGFR mutations detected in malignant pleural effusion, plasma and tumor tissue in patients with adenocarcinoma of the lung.

  2019cites this paper
• Morphological characterization and molecular profiling of malignant pericardial effusion in patients with pulmonary adenocarcinoma

  2019cites this paper
• Discordance of epidermal growth factor receptor mutation between primary lung tumor and paired distant metastases in non-small cell lung cancer: A systematic review and meta-analysis

  2019cites this paper
• Central Nervous System Metastases in Lung Cancer Patients: From Prevention to Diagnosis and Treatment

  2019cites this paper
• Driver genes as predictive indicators of brain metastasis in patients with advanced NSCLC: EGFR, ALK, and RET gene mutations

  2019cites this paper
• Malignant Pleural Effusion from Lung Cancers with Driver Mutations

  2018cites this paper
• The correlation between crizotinib efficacy and molecular heterogeneity by next-generation sequencing in non-small cell lung cancer.

  2018cites this paper
• Clinical Characteristics and Survival Outcomes for Non-Small-Cell Lung Cancer Patients with Epidermal Growth Factor Receptor Double Mutations

  2018cites this paper
• Identification of EGFR mutations in cytological specimens of non-small cell lung carcinoma from a single institute.

  2018cites this paper
• Risk factors for brain metastases in patients with non–small‐cell lung cancer

  2018cites this paper
• Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment.

  2018cites this paper
• Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment.

  2018cites this paper
• Toward Precision Medicine in Brain Metastases

  2018cites this paper
• Potential Molecular Signatures Predictive of Lung Cancer Brain Metastasis

  2018cites this paper
• Effect of platinum-based chemotherapy on EGFR gene mutation status in lung adenocarcinoma

  2018cites this paper
• Deciphering Clinicoradiologic Phenotype for Thymidylate Synthase Expression Status in Patients with Advanced Lung Adenocarcinoma Using a Radiomics Approach

  2018cites this paper
• Overview of metastatic disease of the central nervous system.

  2018cites this paper
• Leptomeningeal metastasis from systemic cancer: Review and update on management

  2018cites this paper
• Heterogeneity in Lung Cancer

  2018cites this paper
• Management of Brain Metastases in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer

  2018cites this paper
• Comparable clinical outcomes in patients with HER2‐mutant and EGFR‐mutant lung adenocarcinomas

  2017cites this paper
• Comparison of the c‐MET gene amplification between primary tumor and metastatic lymph nodes in non‐small cell lung cancer

  2017cites this paper
• A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population.

  2017cites this paper
• Ovarian metastasis from lung adenocarcinoma with ALK-positive rearrangement detected by next generation sequencing: A case report and literatures review

  2017cites this paper
• Role of Autophagy and Apoptosis in Non-Small-Cell Lung Cancer

  2017cites this paper
• Correlation of early PET findings with tumor response to molecular targeted agents in patients with advanced driver-mutated non-small cell lung cancer

  2017cites this paper
• Circulating and disseminated tumor cells: harbingers or initiators of metastasis?

  2017cites this paper
• The effectiveness of EGFR-TKIs against brain metastases in EGFR mutation-positive non-small-cell lung cancer

  2017cites this paper
• METÁSTASIS CEREBRALES: UNA MIRADA BIOLÓGICA Y CLÍNICA

  2017cites this paper
• Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series

  2017cites this paper
• The Current Role of Whole Brain Radiation Therapy in Non–Small Cell Lung Cancer Patients

  2017cites this paper
• PUB062 Risk Factors of Brain Metastasis during the Course of EGFR-TKIs Therapy for Patients with EGFR-Mutated Advanced Lung Adenocarcinoma

  2017cites this paper
• Dynamic Contrast-enhanced MR Imaging Parameters in Bone Metastases from Non-Small Cell Lung Cancer: Comparison between Lesions with and Lesions without Epidermal Growth Factor Receptor Mutation in Primary Lung Cancer.

  2017cites this paper
• Treatment of brain metastases in the modern genomic era

  2017cites this paper
• Lung adenocarcinomas: a novel KRAS/EGFR exon 21 double mutation with limited response to TKI treatment and two rare EGFR exon 19 deletions with variable response

  2016cites this paper
• Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis

  2016cites this paper
• Brain metastases from non-small cell lung cancer : radiation therapy in the era of targeted therapies

  2016cites this paper
• Mutational status of synchronous and metachronous tumor samples in patients with metastatic non-small-cell lung cancer

  2016cites this paper
• Correlation between status of epidermal growth factor receptor mutation and distant metastases of lung adenocarcinoma upon initial diagnosis based on 1063 patients in China

  2016cites this paper
• High concordance of ALK rearrangement between primary tumor and paired metastatic lymph node in patients with lung adenocarcinoma.

  2016cites this paper
• Epidermal Growth Factor Receptor遺伝子変異検出に肺生検標本を用いる場合の問題点

  2016cites this paper
• The IASLC Lung Cancer Staging Project: Background Data and Proposed Criteria to Distinguish Separate Primary Lung Cancers from Metastatic Foci in Patients with Two Lung Tumors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer

  2016cites this paper
• Favorable response in “locally advanced stage” of adenocarcinoma lung to erlotinib: Quality of life and clinical and radiological outcome are satisfactory after 24 weeks

  2016cites this paper
• Impact of Deferring Radiation Therapy in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer Who Develop Brain Metastases.

  2016cites this paper
• Tumour heterogeneity: principles and practical consequences

  2016cites this paper
• Evolution of Metastatic Disease: The Need for Monitoring and Emerging Therapeutic Opportunities

  2016cites this paper
• Coexistence of an EGFR Mutation and an ALK Rearrangement in a Patient with Lung Adenocarcinoma: a Case Report

  2016cites this paper
• Brain Metastases from NSCLC: Radiation Therapy in the Era of Targeted Therapies

  2016cites this paper
• Targeted adjuvant therapy in breast cancer

  2016cites this paper
• Icotinib, an EGFR-TKI, for the treatment of brain metastases in non-small cell lung cancer: a retrospective study

  2016cites this paper
• Risk factors of brain metastasis during the course of EGFR-TKIs therapy for patients with EGFR-mutated advanced lung adenocarcinoma

  2016cites this paper
• EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

  2015cites this paper
• LDA-SVM-Based EGFR Mutation Model for NSCLC Brain Metastases

  2015cites this paper
• Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations

  2015cites this paper